We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment... Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States. Show more
CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025 PR Newswire CAMBRIDGE, Mass., Oct. 10, 2024 Designed to help dialysis organizations incorporate new treatments...
Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis PR Newswire CAMBRIDGE, Mass., Oct. 7, 2024 U.S. Renal...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass., Oct. 1, 2024 CAMBRIDGE, Mass., Oct. 1, 2024 /PRNewswire/ -- Akebia Therapeutics®...
Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis PR Newswire CAMBRIDGE, Mass., Sept. 5, 2024 Outcomes study will assess mortality...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass., Sept. 3, 2024 CAMBRIDGE, Mass., Sept. 3, 2024 /PRNewswire/ -- Akebia...
Akebia Therapeutics to Present at Upcoming Investor Conferences PR Newswire CAMBRIDGE, Mass., Aug. 26, 2024 CAMBRIDGE, Mass., Aug. 26, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq:...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0201 | -1.49988806805 | 1.3401 | 1.37 | 1.255 | 856702 | 1.3070786 | CS |
4 | -0.13 | -8.96551724138 | 1.45 | 1.485 | 1.24 | 1236940 | 1.33912447 | CS |
12 | -0.025 | -1.85873605948 | 1.345 | 1.58 | 1.07 | 1623309 | 1.37456338 | CS |
26 | -0.23 | -14.8387096774 | 1.55 | 1.58 | 0.8 | 2496298 | 1.2290643 | CS |
52 | 0.26 | 24.5283018868 | 1.06 | 2.48 | 0.7801 | 2779632 | 1.412392 | CS |
156 | -1.51 | -53.3568904594 | 2.83 | 3.35 | 0.241 | 3664132 | 1.06501815 | CS |
260 | -2.87 | -68.4964200477 | 4.19 | 13.78 | 0.241 | 3627600 | 2.29416001 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions